vs
Apellis Pharmaceuticals, Inc.（APLS）与ESSENTIAL PROPERTIES REALTY TRUST, INC.（EPRT）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是ESSENTIAL PROPERTIES REALTY TRUST, INC.的1.3倍（$199.9M vs $158.8M），ESSENTIAL PROPERTIES REALTY TRUST, INC.净利率更高（37.8% vs -29.5%，领先67.2%），ESSENTIAL PROPERTIES REALTY TRUST, INC.同比增速更快（22.8% vs -5.9%），过去两年ESSENTIAL PROPERTIES REALTY TRUST, INC.的营收复合增速更高（20.6% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Essential Properties Realty Trust是一家上市房地产投资信托企业，收购、持有并管理美国全境的单租户净租赁商业地产组合，资产主要覆盖休闲餐饮、汽车服务、医疗诊所、幼儿教育中心、轻型工业等刚需服务类业态，租户普遍拥有稳健的长期经营记录。
APLS vs EPRT — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $158.8M |
| 净利润 | $-59.0M | $60.0M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 56.5% |
| 净利率 | -29.5% | 37.8% |
| 营收同比 | -5.9% | 22.8% |
| 净利润同比 | -62.2% | 6.5% |
| 每股收益（稀释后） | $-0.40 | $0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $158.8M | ||
| Q4 25 | $199.9M | $149.9M | ||
| Q3 25 | $458.6M | $144.9M | ||
| Q2 25 | $178.5M | $137.1M | ||
| Q1 25 | $166.8M | $129.4M | ||
| Q4 24 | $212.5M | $119.7M | ||
| Q3 24 | $196.8M | $117.1M | ||
| Q2 24 | $199.7M | $109.3M |
| Q1 26 | — | $60.0M | ||
| Q4 25 | $-59.0M | $68.1M | ||
| Q3 25 | $215.7M | $65.6M | ||
| Q2 25 | $-42.2M | $63.2M | ||
| Q1 25 | $-92.2M | $56.1M | ||
| Q4 24 | $-36.4M | $55.4M | ||
| Q3 24 | $-57.4M | $49.1M | ||
| Q2 24 | $-37.7M | $51.5M |
| Q1 26 | — | 56.5% | ||
| Q4 25 | -25.6% | 65.9% | ||
| Q3 25 | 48.7% | 64.7% | ||
| Q2 25 | -18.6% | 64.1% | ||
| Q1 25 | -50.0% | 61.6% | ||
| Q4 24 | -12.3% | 66.1% | ||
| Q3 24 | -24.0% | 59.7% | ||
| Q2 24 | -14.7% | 61.1% |
| Q1 26 | — | 37.8% | ||
| Q4 25 | -29.5% | 45.4% | ||
| Q3 25 | 47.0% | 45.3% | ||
| Q2 25 | -23.6% | 46.1% | ||
| Q1 25 | -55.3% | 43.4% | ||
| Q4 24 | -17.1% | 46.3% | ||
| Q3 24 | -29.2% | 42.0% | ||
| Q2 24 | -18.9% | 47.1% |
| Q1 26 | — | $0.28 | ||
| Q4 25 | $-0.40 | $0.34 | ||
| Q3 25 | $1.67 | $0.33 | ||
| Q2 25 | $-0.33 | $0.32 | ||
| Q1 25 | $-0.74 | $0.29 | ||
| Q4 24 | $-0.30 | $0.31 | ||
| Q3 24 | $-0.46 | $0.27 | ||
| Q2 24 | $-0.30 | $0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $15.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $4.4B |
| 总资产 | $1.1B | $7.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | — | $15.2M | ||
| Q4 25 | $466.2M | $60.2M | ||
| Q3 25 | $479.2M | $23.8M | ||
| Q2 25 | $370.0M | $20.8M | ||
| Q1 25 | $358.4M | $47.0M | ||
| Q4 24 | $411.3M | $40.7M | ||
| Q3 24 | $396.9M | $32.7M | ||
| Q2 24 | $360.1M | $23.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $1.9B |
| Q1 26 | — | $4.4B | ||
| Q4 25 | $370.1M | $4.2B | ||
| Q3 25 | $401.2M | $3.8B | ||
| Q2 25 | $156.3M | $3.8B | ||
| Q1 25 | $164.2M | $3.8B | ||
| Q4 24 | $228.5M | $3.6B | ||
| Q3 24 | $237.1M | $3.2B | ||
| Q2 24 | $264.3M | $3.2B |
| Q1 26 | — | $7.2B | ||
| Q4 25 | $1.1B | $6.9B | ||
| Q3 25 | $1.1B | $6.6B | ||
| Q2 25 | $821.4M | $6.3B | ||
| Q1 25 | $807.3M | $6.1B | ||
| Q4 24 | $885.1M | $5.8B | ||
| Q3 24 | $901.9M | $5.5B | ||
| Q2 24 | $904.5M | $5.3B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.69× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.56× | ||
| Q4 24 | — | 0.60× | ||
| Q3 24 | — | 0.69× | ||
| Q2 24 | — | 0.59× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $381.1M | ||
| Q3 25 | $108.5M | $99.0M | ||
| Q2 25 | $4.4M | $99.8M | ||
| Q1 25 | $-53.4M | $77.2M | ||
| Q4 24 | $19.4M | $308.5M | ||
| Q3 24 | $34.1M | $73.5M | ||
| Q2 24 | $-8.3M | $81.1M |
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 5.60× | ||
| Q3 25 | 0.50× | 1.51× | ||
| Q2 25 | — | 1.58× | ||
| Q1 25 | — | 1.38× | ||
| Q4 24 | — | 5.57× | ||
| Q3 24 | — | 1.50× | ||
| Q2 24 | — | 1.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
EPRT
| Rental revenue 1,2 | $149.4M | 94% |
| Other | $8.6M | 5% |
| Other revenue | $779.0K | 0% |
